MARKHAM, ON, July 26, 2017 /CNW/ - MedReleaf Corp. (TSX:
LEAF), North America's first and
only ISO 9001 and ICH-GMP certified producer of cannabis-based
pharmaceutical products, today announced that it will hold a
conference call to discuss its first quarter fiscal 2018 results on
Monday, August 14, 2017 at
8:00 a.m. (ET). The call will be
hosted by Neil Closner, Chief
Executive Officer, and Igor
Gimelshtein, Chief Financial Officer, followed by a question
and answer period. MedReleaf will report its financial results in
the morning prior to the call.
First Quarter Fiscal 2018 Conference Call Details:
Date:
|
Monday, August 14,
2017
|
Time:
|
8:00 a.m.
(ET)
|
Dial in
number:
|
(647) 427-7450 or
1-888-231-8191
|
Live
webcast:
|
http://bit.ly/2eEMhiZ
Webcast will be
archived for 90 days
|
Replay:
|
1-855-859-2056
Available until
August 21, 2017
|
Replay
passcode:
|
59994102
|
Forward Looking Statements
This press release contains "forward-looking information" within
the meaning of applicable Canadian securities legislation which are
based upon MedReleaf's current internal expectations, estimates,
projections, assumptions and beliefs and views of future events.
Forward-looking information can be identified by the use of
forward-looking terminology such as "expect", "likely", "may",
"will", "should", "intend", "anticipate", "potential", "proposed",
"estimate" and other similar words, including negative and
grammatical variations thereof, or statements that certain events
or conditions "may", "would" or "will" happen, or by discussions of
strategy. Forward-looking information include estimates, plans,
expectations, opinions, forecasts, projections, targets, guidance
or other statements that are not statements of fact.
Any forward-looking information speaks only as of the date on
which it is made, and, except as required by law, MedReleaf does
not undertake any obligation to update or revise any
forward-looking information, whether as a result of new
information, future events or otherwise. New factors emerge from
time to time, and it is not possible for MedReleaf to predict all
such factors. When considering these forward-looking statements,
readers should keep in mind the risk factors and other cautionary
statements in MedReleaf's Final Long Form Prospectus dated
May 30, 2017 and filed with the
applicable Canadian securities regulatory authorities on SEDAR
at www.sedar.com. The risk factors and other factors noted in
MedReleaf's Final Long Form Prospectus could cause actual events or
results to differ materially from those described in any
forward-looking information.
About MedReleaf Corp.
MedReleaf sets The Medical Grade Standardâ„¢ for cannabis in
Canada and around the world. The
first and only ICH-GMP and ISO 9001 certified producer of
cannabis-based pharmaceutical products in North America, MedReleaf is a R&D-driven
company dedicated to patient care, scientific innovation, research
and advancing the understanding of the therapeutic benefits of
cannabis. Sourced from around the world and perfected in one of two
state of the art facilities in Ontario, MedReleaf delivers a variety of
premium products to patients seeking safe, consistent and effective
medical cannabis.
For more information on MedReleaf, its products, research and
how the company is helping patients #livefree, please visit
MedReleaf.com or follow @medreleafcanada
SOURCE MedReleaf Corp.